Top in endocrinology: Aldosterone antagonists, hormone deficiency
Mineralocorticoid receptor antagonists have an important role in diabetic kidney disease and related cardiovascular consequences, according to a speaker at the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease.
A review of recent data on mineralocorticoid receptor antagonists was the top story in endocrinology last week.
The second top story discussed how vitamin D and thyroid hormone deficiencies could potentially decrease the efficacy of agents such as statins and SGLT2 inhibitors.
Read these and more top stories in endocrinology below:
Aldosterone antagonists play ‘central role’ in heart, kidney disease
Mineralocorticoid receptor antagonists, particularly the most recently approved agent finerenone (Kerendia, Bayer), should play a “central role” in the treatment of diabetic kidney disease and its related cardiovascular consequences, according to a speaker. Read more.
Hormone deficiency may negatively alter response to statin therapy
Vitamin D and thyroid hormones are important modulators in the treatment of CVD and should be incorporated into clinical decision making, according to a speaker. Read more.
Blood pressure variability independent predictor of fracture
A database analysis of more than 3 million South Korean adults shows BP variability is an independent predictor of fracture incidence during 7 years of follow-up, even among adults without hypertension. Read more.
Most young adults attempting weight loss regained weight at 3 years
More than half of young adults participating in a weight-loss intervention had a weight gain above baseline at 3 years, according to study data published in Obesity. Read more.
Thyroid symptoms, quality of life improve after total thyroidectomy with Graves’ disease
Adults with Graves’ disease who undergo a total thyroidectomy experience improvements in quality of life and thyroid-specific symptoms both shortly after and longer after surgery, according to findings published in Thyroid. Read more.